Weight management in type 2 diabetes mellitus

Mount Sinai Journal of Medicine

Volumn 77, Issue 5, 2010, Pages 533-548

  Siram, Amulya T ^a   Yanagisawa, Robert ^a   Skamagas, Maria ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

enteroendocrine axis; metabolic syndrome; obesity; type 2 diabetes mellitus; weight management

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALBUMIN; AMYLIN DERIVATIVE; CHLORPROPAMIDE; CHOLESTEROL; CREATININE; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIPID; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL DISCOMFORT; AEROBIC EXERCISE; BEHAVIOR MODIFICATION; BLOOD PRESSURE; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATININE URINE LEVEL; CULTURAL FACTOR; DIARRHEA; DRUG DOSE REDUCTION; EXERCISE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEALTH BEHAVIOR; HEALTH EDUCATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOOSE FECES; MENTAL DISEASE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL COUNSELING; NUTRITIONAL STATUS; OBESITY; PHYSICAL ACTIVITY; RESISTANCE TRAINING; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; URINARY TRACT INFECTION; VOMITING; WEIGHT CONTROL; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; LIFE STYLE; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 78449257665     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20208     Document Type: Review

References (122)

1. Morris RD, Rimm DL, Hartz AJ, et al., Obesity and heredity in the etiology of non-insulin dependent diabetes mellitus in 32,662 adult white women. Am J Epidemol 1989; 130: 112 - 121.
2. Skarfors ET, Selinus KI, Lithell HO., Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 1991; 303: 755 - 760.
3. Charles MA, Fontbonne A, Thibult N, et al., Risk factors for NIDDM in white population: Paris prospective study. Diabetes 1991; 40: 796 - 799.
4. Alberti KG, Zimmet PZ., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15: 539 - 553.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486 - 2497.
6. Alberti KG, Zimmet P, Shaw J,; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome'a new worldwide definition. Lancet 2005; 366: 1059 - 1062.
7. Anderson JW, Konz EC., Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9: 326S - 334S.
8. Fox CS, Pencina MJ, Wilson PW, et al., Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008; 31: 1582 - 1584.
9. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al., Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009; 52: 65 - 73.
10. Bonora E, Targher G, Formentini F, et al., The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21: 52 - 58.
11. Bonadonna RC, Cucinotta D, Dedele D, et al,; for Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 2006; 29: 2701 - 2707.
12. Knowler WC, Barrett-Connor E, Fowler SE, et al,; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346: 393 - 403.
13. Goldberg RB, Temprosa M, Haffner S, et al., Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009; 32: 726 - 732.
14. Williams KV, Kelley DE., Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000; 2: 121 - 129.
15. Klein S, Sheard NF, Pi-Sunyer X, et al., Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. Diabetes Care 2004; 27: 2067 - 2073.
16. Anderson JW, Kendall CW, Jenkins DJ., Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331 - 339.
17. Norris SL, Zhang X, Avenell A, et al., Long term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117: 762 - 774.
18. Ryan M, Livingstone MB, Ducluzeau PH, et al., Is a failure to recognize an increase in food intake a key to understanding insulin-induced weight gain? Diabetes Care 2008; 31: 448 - 450.
19. Close EJ, Wiles PG, Lockton JA, et al., The degree of day-to day variation in food intake in diabetic patients. Diabet Med 1993; 10: 514 - 520.
20. Ford ES, Herman WH., Leisure-time physical activity patterns in the U.S. diabetic population. Diabetes Care 1995; 18: 27 - 33.
21. Hays LM, Clark DO., Correlates of physical activity in a sample of older adults with type 2 diabetes. Diabetes Care 1999; 22: 706 - 712.
22. Sigal RJ, Kenny GP, Boulé; NG, et al., Effects of aerobic training, resistance training or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007; 147: 357 - 369.
23. Boulé; NG, Haddad E, Kenny GP, et al., Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001; 286: 1218 - 1227.
24. Payne WR, Walsh KJ, Harvey JT, et al., Effect of a low-resource-intensive lifestyle modification program incorporating gymnasium-based and home-based resistance training on type 2 diabetes risk in Australian adults. Diabetes Care 2008; 31: 2244 - 2250.
25. Praet SF, van Rooij ES, Wijtvliet A, et al., Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2008; 51: 736 - 746.
26. Guare JC, Wing RR, Grant A., Comparison of obese NIDDM and nondiabetic women: short-and long-term weight loss. Obesity Res 1995; 3: 329 - 335.
27. Bitz C, Toubro S, Larsen TM, et al., Increased 24-h energy expenditure in type 2 diabetes. Diabetes Care 2004; 27: 2416 - 2421.
28. Pi-Sunyer X, Blackburn G, Brancati FL, et al.,; for the Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007; 30: 1374 - 1383.
29. Redmon JB, Bertoni AG, Connelly S, et al.,; for the Look AHEAD Research Group. Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2010; 33: 1153 - 1158.
30. Norris SL, Lau J, Smith SJ, et al., Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 2002; 25: 1159 - 1171.
31. Wishnofsky M., Caloric equivalents of gained or lost weight. Am J Clin Nutr 1958; 6: 542 - 546.
32. Camelon KM, Hådell K, Jåmsén PT, et al.,; DAIS Project Group. The Plate Model: a visual method of teaching meal planning. Diabetes Atherosclerosis Intervention Study. J Am Diet Assoc 1998; 98: 1155 - 1158.
33. American Diabetes Association. Standards of Medical Care in Diabetes'2010 [published correction appears in Diabetes Care 2010;33:692]. Diabetes Care 2010; 33 (suppl 1): S11 - S61.
34. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 (suppl 1): S61 - S78.
35. Bravata DM, Smith-Spangler C, Sundaram V, et al., Using pedometers to increase physical activity and improve health: a systematic review. JAMA 2007; 298: 2296 - 2304.
36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet 1999;354:602]. Lancet 1998; 352: 837 - 853.
37. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet 1998;352:1558]. Lancet 1998; 352: 854 - 865.
38. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977 - 986.
39. Purnell JQ, Hokanson JE, Marcovina SM, et al., Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial [published correction appears in JAMA 1998;280:1484]. JAMA 1998; 280: 140 - 146.
40. Holman RR, Paul SK, Bethel MA, et al., 10-year follow up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577 - 1589.
41. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643 - 2653.
42. Gerstein HC, Miller ME, Byington RP, et al.,; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545 - 2559.
43. Patel A, MacMahon S, Chalmers J, et al.,; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560 - 2572.
44. Duckworth W, Abraira C, Mortiz T, et al.,; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes [published corrections appear in N Engl J Med 2009; 361: 1028 and 2009;361:1024-1025]. N Engl J Med 2009; 360: 129 - 139.
45. Nichols GA, Gomez-Caminero A., Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007; 9: 96 - 102.
46. Nathan DM, Buse JB, Davidson MB, et al., Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193 - 203.
47. Purnell JQ, Weyer C., Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003; 2: 33 - 47.
48. Johansen K., Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999; 22: 33 - 37.
49. Inzucchi SE, Maggs DG, Spollett GR, et al., Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867 - 872.
50. DeFronzo RA, Goodman AM., Efficacy of metformin in patients with NIDDM. N Engl J Med 1995; 333: 541 - 549.
51. Relimpio F, Pumar A, Losada F, et al., Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial. Diabet Med 1998; 15: 997 - 1002.
52. Avilés-Santa L, Sindig J, Raskin P., Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182 - 188.
53. Stumvoll M, Nurjhan N, Perriello G, et al., Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550 - 554.
54. Hermann LS, Scherstén B, Bitzén PO, et al., Thera- peutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994; 17: 1100 - 1109.
55. Dornan TL, Heller SR, Peck GM, Tattersall RB., Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991; 14: 342 - 344.
56. Evans JM, Donnelly LA, Emslie-Smith AM, et al., Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304 - 1305.
57. Wulffelé MG, Kooy A, de Zeeuw D, et al., The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004; 256: 1 - 14.
58. Lee A, Morley JE., Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6: 47 - 53.
59. Green BD, Irwin N, Duffy NA, et al., Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006; 547: 192 - 199.
60. Hinke SA, Kühn-Wache K, Hoffmann T, et al., Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302 - 1308.
61. Lee A, Patrick P, Wishart J, et al., The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002; 329 - 335.
62. Krentz AJ, Bailey CJ., Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385 - 411.
63. Hoffmann J, Spengler M., 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patents. The Essen study. Diabetes Care 1994; 17: 561 - 566.
64. Hoffman J, Spengler M., Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II study. Am J Med 1997; 103: 483 - 490.
65. Wolever TM, Chiasson JL, Josse RG, et al., Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997; 21: 756 - 763.
66. Van de Laar FA, Lucassen PL, Akkermans RP, et al., Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154 - 163.
67. Hanefeld M, Cagatay M, Petrowitsch T, et al., Acarbose reduces risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10 - 16.
68. Ceriello A, Hanefeld M, Leiter L, et al., Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004; 164: 2090 - 2095.
69. Kahn SE, Haffner SM, Heise MA, et al.,; for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427 - 2444.
70. UKPDS Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165 - 175.
71. Tzoulaki I, Molokhia M, Curcin V, et al., Risk of cardiovascular disease and all-cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
72. Rosenstock J, Hassman DR, Madder RD, et al., Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27: 1265 - 1270.
73. Horvath K, Jeitler K, Berghold A, et al., Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD005613.
74. Heise T, Nosek L, Rønn BB, et al., Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614 - 1620.
75. Rosenstock J, Davies M, Home PD, et al., A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408 - 416.
76. Hollander P, Cooper J, Bregnhøj J, Pedersen CB., A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976 - 1987.
77. Swinnen SG, Dain MP, Aronson R, et al., A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inade- quately controlled on oral glucose-lowering drugs. Diabetes Care 2010; 33: 1176 - 1178.
78. Raslová K, Tamer SC, Clauson P, Karl D., Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007; 27: 279 - 285.
79. Wulffelé MG, Kooy A, Lehert P, et al., Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133 - 2140. (Pubitemid 41071017)
80. Holman RR, Farmer AJ, Davies MJ, et al., Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736 - 1747.
81. Mitri J, Hamdy O., Diabetes medications and body weight. Expert Opin Drug Saf 2009; 8: 573 - 584.
82. Vasudevan AR, Balasubramanyam A., Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy and tolerability. Diabetes Technol Ther 2004; 6: 850 - 863.
83. Yki-Jårvinen H., Thiazolidinediones. N Engl J Med 2004; 351: 1106 - 1118.
84. Phillips SA, Ciaraldi TP, Kong AP, et al., Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52: 667 - 674.
85. Aronoff S, Rosenblatt S, Braithwaite S, et al., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605 - 1611.
86. Van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ., Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744 - 1749.
87. Giles TD, Sander GE., Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep 2007; 9: 332 - 337.
88. Lebovitz HE, Dole JF, Patwardhan R, et al., Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280 - 288.
89. Komajda M, McMurray JJ, Beck-Nielsen H, et al., Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824 - 831.
90. Nissen SE, Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med 2007;357:100]. N Engl J Med 2007; 356: 2457 - 2471.
91. Diamond GA, Bax L, Kaul S., Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147: 578 - 581.
92. Douglas IJ, Evans SJ, Pocock S, Smeeth L., The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009; 6: e1000154.
93. Dormuth CR, Carney G, Carleton B, et al., Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169: 1395 - 1402.
94. Drucker DJ., The biology of incretin hormones. Cell Metab 2006; 3: 153 - 165.
95. Vilsbøll T, Krarup T, Deacon CF, et al., Reduced postprandial concentrations of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 2001; 50: 609 - 613.
96. Buse JB, Henry RR, Han J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628 - 2635.
97. Kendall DM, Riddle MC, Rosenstock J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083 - 1091.
98. DeFronzo RA, Ratner RE, Han J, et al., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092 - 1100.
99. Zinman B, Hoogwerf BJ, Durán García S, et al., The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial [published correction appears in Ann Intern Med 2007;146:896]. Ann Intern Med 2007; 146: 477 - 485.
100. Moretto TJ, Milton DR, Ridge TD, et al., Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study [published correction appears in Clin Ther 2008;30:1937]. Clin Ther 2008; 30: 1448 - 1460.
101. Klonoff DC, Buse JB, Nielsen LL, et al., Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275 - 286.
102. Nauck M, Frid A, Hermansen K, et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32: 84 - 90.
103. Marre M, Shaw J, Bråndle M, et al.,; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes. Diabet Med 2009; 26: 268 - 278.
104. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K., Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 81: 161 - 168.
105. Garber A, Henry R, Ratner R, et al.,; LEAD-3 (Mono) Study Group. Liraglutide versus glimiperide monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473 - 481.
106. Blonde L, Russell-Jones D., The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11 (suppl 3): 26 - 34.
107. Drucker DJ, Nauck MA., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696 - 1705.
108. Ayoub WA, Kumar AA, Naguib HS, Taylor HC., Exenatide-induced acute pancreatitis. Endocr Pract 2010; 16: 80 - 83.
109. Drucker JD, Sherman SI, Gorelick FS, et al., Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33: 428 - 433.
110. Nauck MA, Meininger G, Sheng D, et al., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194 - 205.
111. Raz I, Hanefeld M, Xu L, et al., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564 - 2571.
112. Goldstein B, Feinglos M, Lunceford JK, et al., Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979 - 1987.
113. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C., Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008; 4: 753 - 768.
114. Amori RE, Lau J, Pittas AG., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194 - 206.
115. Young A., Tissue expression and secretion of amylin. Adv Pharmacol 2005; 52: 19 - 45.
116. Juhl CB, Pørksen N, Sturis J, et al., High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab 2000; 278: E484 - E490.
117. Fineman MS, Koda JE, Shen LZ, et al., The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51: 636 - 641.
118. Kong MF, Stubbs TA, King P, et al., The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998; 41: 577 - 583.
119. Chapman I, Parker B, Doran S, et al., Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838 - 848.
120. Ratner RE, Want LL, Fineman MS, et al., Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51 - 61.
121. Hollander PA, Levy P, Fineman MS, et al., Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26: 784 - 790.
122. Riddle M, Frias J, Zhang B, et al., Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007; 30: 2794 - 2799. (Pubitemid 350083120)